All Drug Discovery articles – Page 16
-
ArticleTargeting GLP-1 in the brain could transform obesity care
What if a single hormone could control appetite in two entirely different ways? Professor Stefan Trapp of University College London reveals how GLP-1’s dual role in the brain and gut could transform obesity treatment.
-
ArticleStrategic planning in ADC development: insights from Lonza
Preclinical and clinical development are critical to the success of ADCs, where early strategic decisions regarding manufacturability and scalability can make or break a project. Iwan Bertholjotti of Lonza emphasises the importance of proactive planning to avoid costly delays and ensure smooth progress towards clinical success.
-
ArticleWhat SLAS 2025 really told us about drug discovery
Forget the buzzwords - SLAS 2025 showed what’s genuinely driving progress in drug discovery: usable AI, collaborative platforms and tools that solve real problems.
-
NewsWhy ATP signalling might change melanoma for good
A new study from Central South University reveals how adenosine phosphate signalling shapes the tumour microenvironment in melanoma, offering a new biomarker for guiding personalised cancer treatment.
-
ArticleNew fixed-duration therapy could reshape CLL care
Advancements in chronic lymphocytic leukaemia (CLL) treatment, like the AMPLIFY Phase III trial combining acalabrutinib and venetoclax, offer less toxic and more effective options. Learn from AstraZeneca’s Benjamin Moutier about how this breakthrough highlights the potential of targeted therapies to improve outcomes and reduce treatment burden, marking a key moment ...
-
ArticleTackling complex manufacturing challenges in modern drug development
Chief Scientific Officer at Solvias reveals how CROs are overcoming manufacturing challenges and harnessing AI to fast-track the development of groundbreaking cell and gene therapies.
-
ArticleHow AI and LLMs are transforming drug discovery: part 2
As AI reshapes scientific work, two founders debate how best to build tools scientists can trust — should we embed expertise into the model or the team? From agent-powered labs to hypothesis-generating machines, the future of drug discovery is being reimagined right now.
-
NewsNew investigational therapy shows promise for treating skeletal disorders
Tyra Biosciences has announced new data showing that its investigational therapy, TYRA-300, improves bone growth and corrects skeletal abnormalities in preclinical models of achondroplasia and hypochondroplasia.
-
NewsELRIG's Drug Discovery 2025 announces event speakers
ELRIG has announced the keynote speakers for Drug Discovery 2025, its flagship life sciences event taking place in Liverpool, England this October.
-
NewsTargeting PLA2G15 to treat neurometabolic disorders
Scenic Biotech and Stanford University have published a study identifying PLA2G15 as a new drug target in neurodegenerative and metabolic diseases, potentially enabling future treatments for conditions like Niemann-Pick type C.
-
NewsTargeting the clock: new drug disrupts glioblastoma stem cells
Scientists have developed a new drug, SHP1705, that targets hijacked circadian clock proteins used by glioblastoma stem cells to grow and resist treatment.
-
News
Enedra secures funding to advance AI-driven cancer platform
Enedra Therapeutics has secured new funding to advance its AI-driven CASPAROV platform, aimed at developing therapies for difficult-to-treat cancers
-
ArticleHow AI and LLMs are transforming drug discovery: part 1
AI is reshaping drug discovery – but not without resistance. In this two-part conversation, André França and Eli Pollock share honest insights about the real barriers to AI adoption in life sciences and how embedding domain expertise into AI workflows might be the key to unlocking its full potential.
-
NewsHigh-throughput NaV1.9 assay to advance pain therapies
Metrion Biosciences has introduced a breakthrough NaV1.9 screening assay, aimed at overcoming historical challenges in pain research and advancing the development of non-opioid treatments.
-
NewsEli Lilly backs Creyon’s quantum chemistry platform in $1B RNA drug deal
The partnership allows for the further development of AI-designed RNA-targeted therapies for a range of diseases.
-
NewsNew plasma therapy fights aggressive soft tissue cancer
Researchers at Osaka Metropolitan University have found that plasma-activated medium (PAM) significantly reduces synovial sarcoma tumour growth in both lab and animal models, offering a promising new approach for treating this rare and aggressive cancer.
-
ArticleAllele-selective gene editing: a breakthrough in Huntington's disease treatment
Huntington's disease remains a major challenge, but allele-selective gene editing offers new hope. By targeting only the mutant gene, this approach could provide a one-time, durable treatment. Life Edit’s Dr Amy Pooler reveals how this innovative therapy could reshape HD treatment.
-
NewsScientists develop immunotherapy to disarm fat-fuelled tumours
A new study reveals how tumours hijack fat metabolism to suppress immune responses - and how a novel antibody, PLT012, may reverse this effect, offering new hope for treating immunotherapy-resistant cancers.
-
NewsNew dual-targeting strategy shows promise in treating pancreatic cancer
Researchers at the University of Michigan have discovered a powerful combination therapy that eradicates pancreatic tumours in preclinical models, offering hope for new treatments against one of the most treatment-resistant cancers.
-
NewsBlocking nitrosylation boosts treatment for NRAS melanoma
Researchers at Moffitt Cancer Center have discovered that blocking a chemical process called nitrosylation can make aggressive NRAS-mutant melanoma more responsive to treatment.